



## Clinical trial results:

### Investigating the effect of Maraviroc on microbial translocation in HIV-1 infected individuals who are receiving antiretroviral therapy

#### Summary

EudraCT number	2010-023625-38
Trial protocol	GB
Global end of trial date	01 October 2014

#### Results information

Result version number	v1 (current)
This version publication date	09 February 2019
First version publication date	09 February 2019
Summary attachment (see zip file)	FINAL STUDY REPORT (MT Final Study Report.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	JF003
-----------------------	-------

##### Additional study identifiers

ISRCTN number	ISRCTN81045654
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Guy's and St Thomas' NHS Foundation Trust
Sponsor organisation address	Great Maze Pond, London, United Kingdom, SE19RT
Public contact	Dr Julie Fox, Guy's and St Thomas' NHS Foundation Trust, 0044 02071887188, julie.fox@kcl.ac.uk
Scientific contact	Dr Julie Fox, Guy's and St Thomas' NHS Foundation Trust, 0044 02071887188, julie.fox@kcl.ac.uk

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

Analysis stage	Final
Date of interim/final analysis	01 October 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	01 October 2014
Global end of trial reached?	Yes
Global end of trial date	01 October 2014
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

Main objective of the trial:

To determine whether the addition of a CCR5 inhibitor to a stable ART regimen reduces microbial translocation (as determined by plasma bacterial 16s DNA)

Protection of trial subjects:

Patients will be given information regarding which symptoms should alert them to the possibility of a serious adverse event following their biopsies, in particular perforation or bleeding,. In the event of these symptoms they will be advised to attend their local Accident & Emergency Department directly and to take with them their Patient Information Card and/or inform the medical staff that they are participating in a clinical trial and that the research unit needs to be informed of their admission.

Background therapy:

Participants must be stable on antiretroviral therapy for at least 12 months.

Evidence for comparator:

n/a

Actual start date of recruitment	01 May 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	United Kingdom: 10
Worldwide total number of subjects	10
EEA total number of subjects	10

Notes:

---

**Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10

From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were recruited from one clinical site in London during 2014.

### Pre-assignment

Screening details:

Inclusion Criteria:-

Males and females aged between 18-64 stable on antiretroviral therapy for at least 12 months.

Screening CD4+ T cell count below 500 cells/mm.<sup>3</sup>

Screening plasma HIV RNA levels below 100 copies RNA/mL.

Ability and willingness of subject to give provide informed consent.

### Period 1

Period 1 title	Whole Group (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Open label proof of concept trial.

### Arms

Arm title	Full study
-----------	------------

Arm description:

All participants as this is a single arm proof of concept trial.

Arm type	Pilot
Investigational medicinal product name	MARAVIROC
Investigational medicinal product code	
Other name	CELCENTRI
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Maraviroc is marketed as CELSENTRI ® by ViiV Healthcare in film-coated tablets either 150mg or 300 mg in 60 tab pack. Maraviroc dose based on each participants current medications in regimen as per SmPC.

Number of subjects in period 1	Full study
Started	10
Completed	10

## Baseline characteristics

### Reporting groups

Reporting group title	Whole Group
-----------------------	-------------

Reporting group description: -

Reporting group values	Whole Group	Total	
Number of subjects	10	10	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	10	10	
From 65-84 years	0	0	
85 years and over	0	0	
Gender categorical			
Units: Subjects			
Female	0	0	
Male	10	10	

## End points

### End points reporting groups

Reporting group title	Full study
Reporting group description:	
All participants as this is a single arm proof of concept trial.	

### Primary: Microbial Translocation

End point title	Microbial Translocation <sup>[1]</sup>
End point description:	
Level of Microbial translocation as quantified by bacterial 16s DNA PCR at week 24	
End point type	Primary
End point timeframe:	
Week 24 of participation.	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: See attached document for all results data.	

<b>End point values</b>	Full study			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: whole	10			

<b>Attachments (see zip file)</b>	Results/Trial report Feb 17.pdf
-----------------------------------	---------------------------------

### Statistical analyses

No statistical analyses for this end point

### Secondary: Secondary Endpoints

End point title	Secondary Endpoints
End point description:	
<ul style="list-style-type: none"><li>- Level of gut permeability: changes in level of CD14a</li><li>- Immune activation: changes in levels of CD8+CD38+</li><li>- Clinical outcome: CD4+ T cell count change and HIV plasma viral load change.</li><li>- Biomarkers of inflammation: levels of D-dimer</li><li>- Low copy HIV viral quantification</li><li>- Neurocognitive function: memory tests</li><li>- Gut immune reconstitution : Immunohistochemistry</li></ul>	
End point type	Secondary
End point timeframe:	
Week 24 of Participation	

<b>End point values</b>	Full study			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: whole	10			

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Duration of trial

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	17.1
--------------------	------

### Reporting groups

Reporting group title	Whole Trial
-----------------------	-------------

Reporting group description: -

Serious adverse events	Whole Trial		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Whole Trial		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 10 (50.00%)		
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
General disorders and administration site conditions			
Rectal spotting post biopsy			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			



Bursitis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
pain on palpation at sterno-costoclavicular joint associated with signs of sternochondritis			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Severe chest pain			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Infections and infestations			
Eye Infection left eye			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Gonorrhea throat			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Skin Irritation associated with fungal skin infection			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
Syphilis (re-infection)			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		
tooth infection			
subjects affected / exposed	1 / 10 (10.00%)		
occurrences (all)	1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This is a proof of concept unpowered study involving 10 volunteers. The results of which will be used to provide information about the feasibility of conducting a large scale randomised control study. There is currently no pilot data on the effect of
--

Notes:

---

### Online references

<http://www.ncbi.nlm.nih.gov/pubmed/27917639>